Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics, BeiGene Ink CDx Pact

NEW YORK (GenomeWeb) – Myriad Genetics today announced a companion diagnostic development pact with BeiGene, a company developing cancer treatments combining immunotherapy and molecularly targeted drugs.

BeiGene — which is headquartered in Fort Lee, NJ, and has an R&D center in Beijing, China — will use Myriad's myChoice HRD and BRACAnalysis CDx as part of the clinical development program for its investigational PARP inhibitor BGB-290. The drug firm is conducting a study of BGB-290 in combination with its PD-1 inhibitor BGB-A317 for the treatment of cancers driven by perturbed DNA repair mechanisms due to BRCA1 and BRCA2 gene mutations or homologous recombination deficiencies.

The deal with BeiGene adds to Myriad's growing list of companion diagnostics partnerships. The molecular diagnostics firm has inked agreements for BRACAnalysis CDx with at least four other drug firms, including AstraZeneca, Medivation, Tesaro, and AbbVie. Some of these same firms are also using myChoice HRD in their drug studies.